(Q42945956)

English

Long-Term Suppressive Effect of Octreotide on Progression of Metastatic Gastrinoma with Multiple Endocrine Neoplasia Type 1: Seven-Year Follow up

scientific article published on August 2, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Long-Term Suppressive Effect of Octreotide on Progression of Metastatic Gastrinoma with Multiple Endocrine Neoplasia Type 1: Seven-Year Follow up (English)

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

multiple endocrine neoplasia

1 reference

based on heuristic

inferred from title

multiple endocrine neoplasia type 1

1 reference

based on heuristic

inferred from title

9

object named as

Yuji Matsuzawa

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Yoshihiko Hoshida

8

object named as

Yoshihiko Hoshida

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20686291

17 June 2024

author name string

Megu Yamaguchi

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Yuya Yamada

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Yoshiya Hosokawa

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Ryuya Iwamoto

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sachiko Tamba

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Arisa Ihara

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Koji Yamamoto

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

2 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Internal Medicine

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1557-1563

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

2

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas

3

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Gastrinoma (duodenal and pancreatic).

4

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Guidelines for diagnosis and therapy of MEN type 1 and type 2.

5

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Gastrinomas: advances in diagnosis and management

6

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1

7

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Enteropancreatic malignancy associated with multiple endocrine neoplasia type 1: risk factors and pathogenesis

8

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome

9

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan

10

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.

11

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Enteroendocrine tumors other than carcinoid: a review of clinically significant advances

12

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study

14

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.

15

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma

17

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

18

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Multiple endocrine neoplasia type 1: clinical and genetic topics

19

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma

20

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Clinical studies of multiple endocrine neoplasia type 1 (MEN1)

21

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Cause of death in multiple endocrine neoplasia type 1

22

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Clinicopathological characteristics of duodenal microgastrinomas

24

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

New pancreas-preserving total duodenectomy technique

25

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Tumour biology and histopathology of neuroendocrine tumours

26

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

The Ki-67 protein: from the known and the unknown

27

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Ki67 protein: the immaculate deception?

28

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors

29

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Somatostatin and its receptor family

31

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

32

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis

33

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Somatostatin Receptor type 2 Mediates Bombesin‐Induced Inhibition of Gastric Acid Secretion in Mice

34

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors.

35

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

36

1 reference

10.2169/INTERNALMEDICINE.49.3607

https://api.crossref.org/works/10.2169/INTERNALMEDICINE.49.3607

17 June 2024

Identifiers

10.2169/INTERNALMEDICINE.49.3607

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42945956&oldid=2181742901"